Consequences of long-term consumption of water from Nworie River (Owerri, Nigeria) on haematological, hepatic, and renal functions using rat model

The consequences of long term consumption of water from Nworie River (Owerri, Nigeria) on haematological, hepatic, and renal functions using rat model (Wistar albino strain). Twenty-four rats separated into two groups of twelve rats each were kept as test and control for sixty-four days. The test rats were placed on water from Nworie River while those of the control were placed on Eva water (purified Coca-cola bottled water). The rats were sacrificed in two sets: first set was on thirty-second day while the second set was on the sixty-fourth day. Six rats each from each group were sacrificed at each set. The Results obtained revealed that Hb, PCV, WBC, L, N, and ESR were significantly affected (p<0.05) in test rats against the control rats. The functional parameters of liver adequacy; AST, ALT, and ALP were significantly (p<0.05) affected in test rats against those of the control. Also, urea and electrolyte ions (Potassium ion, chloride and bicarbonate) indicating renal sufficiency were significantly (p<0.05) affected in test rats against those of the control. Creatinine, sodium ion, total bilirubin and conjugated bilirubin were not significantly affected (p>0.05) in test rats when compared to those of the control. The induced changes in the parameters investigated in this study have shown that long-term consumption of water from Nworie River has effect on haematological, hepatic, and renal function.KEYWORDS: Nworie River, haematology, liver function, kidney functio

Preparation and characterization of activated carbon from plantain peel and coconut shell using biological activators

A concern over the toxicity of chemicals used during the activation stage in the preparation of activated carbon is beginning to gain attention. The study therefore looked into the possibility of using bio-activators (lemon juice and potash leached from the peel of unripe plantain) as activating chemicals, for environmentally friendly activated carbon. Coconut shell and the peel from unripe plantain were used as feedstock and pyrolyzed at 400 and 450 0c. An impregnation ratio of 0.25:1 was used while laboratory grade potassium hydroxide was used as a base activating agent as a control setup. Characterization of the activated carbon was carried out using parameters like bulk density and yield which were obtained using standard procedures. Results showed that activating carbon using bio-activators as activating agents had very good characteristics when compared with the control. Bio-activators are therefore recommended for the production of bio based activated carbon especially in the fields of medicine, food and pharmaceuticals. The effect of carbonization temperature on adsorption efficiency and pore structure were investigated using methylene blue as adsorbate and SEM respectively

Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children

OBJECTIVE: Our aim was to evaluate the safety, reactogenicity, and immunogenicity of an investigational malaria vaccine. DESIGN: This was an age-stratified phase Ib, double-blind, randomized, controlled, dose-escalation trial. Children were recruited into one of three cohorts (dosage groups) and randomized in 2:1 fashion to receive either the test product or a comparator. SETTING: The study was conducted in a rural population in Kombewa Division, western Kenya. PARTICIPANTS: Subjects were 135 children, aged 12–47 mo. INTERVENTIONS: Subjects received 10, 25, or 50 μg of falciparum malaria protein 1 (FMP1) formulated in 100, 250, and 500 μL, respectively, of AS02A, or they received a comparator (Imovax® rabies vaccine). OUTCOME MEASURES: We performed safety and reactogenicity parameters and assessment of adverse events during solicited (7 d) and unsolicited (30 d) periods after each vaccination. Serious adverse events were monitored for 6 mo after the last vaccination. RESULTS: Both vaccines were safe and well tolerated. FMP1/AS02A recipients experienced significantly more pain and injection-site swelling with a dose-effect relationship. Systemic reactogenicity was low at all dose levels. Hemoglobin levels remained stable and similar across arms. Baseline geometric mean titers were comparable in all groups. Anti-FMP1 antibody titers increased in a dose-dependent manner in subjects receiving FMP1/AS02A; no increase in anti-FMP1 titers occurred in subjects who received the comparator. By study end, subjects who received either 25 or 50 μg of FMP1 had similar antibody levels, which remained significantly higher than that of those who received the comparator or 10 μg of FMP1. A longitudinal mixed effects model showed a statistically significant effect of dosage level on immune response (F(3,1047) = 10.78, or F(3, 995) = 11.22, p < 0.001); however, the comparison of 25 μg and 50 μg recipients indicated no significant difference (F(1,1047) = 0.05; p = 0.82). CONCLUSIONS: The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed 12- to 47-mo-old children and the magnitude of immune response of the 25 and 50 μg doses was superior to that of the 10 μg dose

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-terminal fragment of merozoite surface protein-1 (MSP-1) of the 3D7 clone of P. falciparum. Formulated with AS02 (a proprietary Adjuvant System), it constitutes the FMP1/AS02 candidate malaria vaccine. We evaluated this vaccine's safety, immunogenicity, and efficacy in African children.A randomised, double-blind, Phase IIb, comparator-controlled trial.The trial was conducted in 13 field stations of one mile radii within Kombewa Division, Nyanza Province, Western Kenya, an area of holoendemic transmission of P. falciparum. We enrolled 400 children aged 12-47 months in general good health.Children were randomised in a 1ratio1 fashion to receive either FMP1/AS02 (50 microg) or Rabipur(R) rabies vaccine. Vaccinations were administered on a 0, 1, and 2 month schedule. The primary study endpoint was time to first clinical episode of P. falciparum malaria (temperature >/=37.5 degrees C with asexual parasitaemia of >/=50,000 parasites/microL of blood) occurring between 14 days and six months after a third dose. Case detection was both active and passive. Safety and immunogenicity were evaluated for eight months after first immunisations; vaccine efficacy (VE) was measured over a six-month period following third vaccinations.374 of 400 children received all three doses and completed six months of follow-up. FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator. Geometric mean anti-MSP-1(42) antibody concentrations increased from1.3 microg/mL to 27.3 microg/mL in the FMP1/AS02 recipients, but were unchanged in controls. 97 children in the FMP1/AS02 group and 98 controls had a primary endpoint episode. Overall VE was 5.1% (95% CI: -26% to +28%; p-value = 0.7).FMP1/AS02 is not a promising candidate for further development as a monovalent malaria vaccine. Future MSP-1(42) vaccine development should focus on other formulations and antigen constructs.Clinicaltrials.gov NCT00223990